Renaissance Capital logo

Black Diamond Therapeutics Priced, Nasdaq: BDTX

Phase 1-ready biotech developing targeted kinase inhibitors for solid tumors.

Industry: Health Care

First Day Return: +107.8%

Industry: Health Care

We are a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Our goal is to bring precision oncology medicine to a greater number of patients. We target undrugged mutations in patients with genetically-defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow us to i) analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, ii) group these mutations into families and iii) develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. We have designed our lead product candidate, BDTX-189, to block the function of an undrugged family of oncogenic proteins defined by mutations which occur across a range of tumor types, and which affect both the epidermal growth factor receptor, or EGFR, and the tyrosine-protein kinase ErbB-2, or HER2.
more less
IPO Data
IPO File Date 01/03/2020
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 10.6
Deal Size ($mm) $201
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/29/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $201
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Cambridge, MA, United States
Founded 2014
Employees at IPO 31
Website www.blackdiamondtherapeutics.com

Black Diamond Therapeutics (BDTX) Performance